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Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
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Abstract

Research Questions

• As Klepser, Collier, and Cochran (2013) noted, PPIs are a class of agents that reduce
acid secretion by parietal cells in the stomach by irreversibly blocking H+/K+ adenosine
triphosphate. They are commonly prescribed for many gastrointestinal (GI) conditions
including gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), upper
gastrointestinal bleeding, and Helicobacter pylori infections. They are frequently utilized
in the primary care setting. The purpose of this study was to examine the efficacy, usage,
and current literature on PPIs.
• There were several complications noted with PPI usage. Gomm et al. (2016) found that
that use of PPI is associated with an increased risk of dementia and that avoiding PPIs
may contribute to the prevention of dementia. Klepser et al. (2013) concluded that PPIs
were associated with renal disease after controlling for confounding conditions. They
noted patients who had renal disease were twice as likely to have used PPIs in the past.
In yet another study, Lazarus et al. (2016) concluded that PPI use is an independent risk
factor for CKD and AKI, while H2 antagonist use is not. Shih et al. (2014) concluded PPI
use was associated with an increased risk of myocardial infarction for both a 7- and 14day window period. Finally, van der Hoorn et al. (2015) also determined that PPI use
was associated with a substantially increased risk of requiring osteoporosis medication
and fractures.
• Histamine-2-receptor antagonists (H2RAs) are often prescribed in place of PPIs.
Sigterman et al. (2013) concluded that were superior to H2RAs in treating heartburn in
patients both treated empirically and in patents with endoscopy-negative reflux disease
(ENRD). PPIs were also noted to be more effective in patients requiring long-term
treatment. H2RAs, however, were found to be superior to PPIs in speed of relief of
symptoms and may be a better option for patients with only occasional symptoms.
• Rickenbacher et al. (2014) studied medical vs. surgical management of GERD. Their
data showed a statistically significant pooled effect estimate in favor of fundoplication
over medical management of GERD, although several patients complained of dysphagia
after surgery. Nissen fundoplication has long been the surgical intervention of choice for
GERD treatment. It has some drawbacks in that many patients complain of dysphagia
and bloating post-surgery. Lal et al. (2017) compared laparoscopic Nissen
fundoplication (LNF) to laparoscopic anterior partial fundoplication (LAPF) and found it
to be just as effective as LNF for GERD treatment with less dysphagia.

• In patients with GERD, duodenal and pyloric ulcers, or Helicobacter pylori
infections, is treatment with PPIs more efficacious than treatment with
histamine H2-receptor antagonists?
• In patients with GERD, duodenal and pyloric ulcers, or Helicobacter pylori
infections, is treatment with PPIs more efficacious than surgical treatment?
• Does long-term treatment with PPIs increase a patient’s risk for kidney
failure, dementia, myocardial infarction, or osteoporosis?

• However, Katz, Gerson, and Vella (2013) concluded that five years of previous
PPI usage did not increase risk of osteoporosis in the hip (OR 0.84; 95% CI, 0.551.34) or in the lumbar spine (OR 0.79; 95% CI, 0.59-1.06).
• Also, Targownik et al. (2016) found no difference between PPI users and nonusers after DXA scanning (0.13±0.89 g/cm for PPI users vs. 0.12±1.07 g/cm2,
P>0.2 for the non-PPI users). There was also no difference found in bone mineral
density after CT scanning of the femoral neck. Metabolic markers were found to
be statistically the same for both PPI users and non-users, except for gastrin,
which was higher among PPI users, as expected.

Literature Review

Alternatives to Proton Pump Inhibitor Use

Mechanism of Action of Proton Pump Inhibitors
• Gastric acid secretion is regulated by the proton pump in the parietal cell. The
H+/K+-ATPase pump pushes H+ into the stomach through an ion gradient.
• PPIs are absorbed into systemic circulation in the small intestine. They enter the
parietal cells in the stomach from systemic circulation and are activated by the
acid canaliculi.
• They irreversibly bind to the active proton pumps at the final step of acid
secretion, reducing output.
• The basic chemical structure of a PPI consists of a substituted benzimidazole ring
and a substituted pyridine ring connected to each other by a methylsulfinyl chain.
• The most commonly used PPIs include omeprazole, lansoprazole, rabeprazole,
pantoprazole, and esomeprazole.
• Research is currently being conducted on a new class of reversible PPIs, although
none are available yet. (Jain et al., 2007)

Statement of the Problem
Proton pump inhibitors are very commonly prescribed medications throughout
family practice clinics. Many different PPIs are now available over-thecounter as well. There are many possible diagnoses that may warrant PPI
treatment and many patients take these medications for extended periods
without medical provider supervision. Recently, studies have concluded that
PPIs may have greater risks for patients than originally thought. This has led to
the exploration of other treatment plans for these common GI conditions and
complaints. This research hopes to answer the following research questions
and determine if PPIs are the safest and most efficacious treatment for
common GI conditions such as GERD, both duodenal and pyloric ulcers, and
Helicobacter pylori infections. More research is needed to understand the
interaction between these conditions and the reason for increased symptoms
across the population. There also may be alternative methods of treatment not
yet investigated or fully understood.

• Sigterman et al. (2013) concluded that PPIs (RR 0.37; two trials; 95% CI 0.320.44) were superior to H2RAs (RR 0.77; two trials; 95% CI 0.60-0.99) and
prokinetics (RR 0.86; one trial, 95% CI 0.73-1.01) in placebo controlled trials
treating GORD in patients empirically. In direct comparison, PPIs were more
effective than H2RAs (RR 0.66; seven trials, 95% CI 0.60-0.73) and prokinetics
(RR 0.53; two trials, 95% CI 0.32-.087).
• They also determined that in treating those with ENRD, the RR for heartburn
remission for those treated with PPI vs. those treated with placebo was 0.71 (ten
trials, 95% CI 0.65-0.78) and for H2RA vs placebo was 0.84 (two trials, 95% CI
0.74-0.95). The RR for PPI vs. H2RA was 0.78 (three trials, 95% CI 0.62-0.97)
and for PPI vs. prokinetic it was 0.72 (one trial, 95% CI 0.56-0.92). H2RAs were
noted to be effective, but to a lesser degree. (Sigterman et all., 2013)
• Rickenbacher et al. (2014) showed a statistically significant pooled effect estimate
in favor of fundoplication over medical management of GERD (SMD 0.18; 95%
CI 0.01-0.35).
• Lal et al. (2017) determined that laparoscopic anterior partial fundoplication is as
effective as laparoscopic Nissen Fundoplication for GERD treatment.

Discussion

Introduction
• The stomach is the primary location of digestion, which is achieved through the
release of acids and enzymes. Acid is secreted by the parietal cells.
• Acid-peptic disease is attributed to an imbalance between aggressive factors like
acid, pepsin, and Helicobacter pylori infection, and local mucosal defenses such
as secretion of bicarbonate, mucus, and prostaglandins.
• In western countries, duodenal ulcers are the most common gastrointestinal
complaint, whereas in eastern countries, gastric ulcers are more common.
• We can treat acid-peptic disease by either reducing the aggressive factors, which
is the most common method, or we can bolster the mucosal defenses in the
stomach and duodenum.
• GERD, peptic ulcers, duodenal ulcers, Zollinger-Ellison syndrome, gastritis, and
H. pylori infections are all treated by lowering gastric acid secretion.
• Acid secretion is currently reduced by blocking the acid secretary effect of
histamine.
• This is achieved using two common treatments, H2-receptor agonists or
irreversible H+/K+-ATPase inhibitors. The latter are commonly referred to as
proton pump inhibitors, or PPIs.
• If left untreated, disorders causing elevated gastric acid secretion can have serious
consequences. These include scar tissue formation leading to pyloric stenosis,
bleeding from erosion of small blood vessels, evolution of a gastric ulcer to
cancer, or perforation. Perforation occurs more commonly in duodenal ulcers and
may lead to complications involving other organs. (Jain et al., 2007)
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Possible Complications of Proton Pump Inhibitor Use
• There may be drug interactions leading to decreased absorption of some drugs
like griseofulvin, ketoconazole, vitamin B12, and iron salts. (Jain et al., 2007)
• Gomm et al. (2016) concluded that use of PPI is associated with an increased risk
of dementia (HR 1.44; 95% CI 1.36-1.52; P<0.001) and that avoiding PPIs may
contribute to the prevention of dementia.
• Klepser, Collier, and Cochran (2013) determined that PPIs were associated with
renal disease after controlling for confounding conditions (OR 1.72; 95% CI 1.272.32; p<0.001). They removed patients with potential confounding disease states
from the study population and were still able to statistically validate a relationship
between PPIs and renal disease (OR 2.04; 95% CI 1.09-4.62). They noted patients
who had renal disease were twice as likely to have used PPIs in the past.
• Lazarus et al.(2016) concluded that baseline PPI users were 1.72 times more
likely to experience an acute kidney injury than those who did not use PPIs (95%
CI 1.28-2.30; P<0.001). Twice daily dosing (adjusted HR 1.46; 95% CI 1.09-1.21;
P<0.001) was also associated with a higher risk of CKD when compared to once
daily dosing (adjusted HR 1.15; 95% CI 1.09-1.21; P<0.001). In this group, the
10-year absolute risk of CKD for the 16,900 baseline PPI users was 15.6% and
the absolute risk for non-PPI users for CKD was 13.9%.
• Shih et al. (2014) found that PPI use was associated with an increased risk of MI
for both a 7- (AOR 4.61; 95% CI 1.76-12.07; P=0.002) and 14-day window
period (AOR 3.47, 95% CI 1.76-6.83, P<0.001).
• Van der Hoorn et al. (2015) determined that PPI use was associated with a
substantially increased risk of requiring osteoporosis medication (adjusted subhazard ratio 1.28; 95% CI = 1.13-1.44) and fractures (adjusted sub-hazard ratio
1.29; 95% CI = 1.08-1.55).

• Research continues of the possible consequences of PPI use and alternative
treatments.
• Research revealed PPIs are more efficacious than treatment with histamine H2receptor antagonists and prokinetics.
• H2RAs were suggested as an effective treatment option for those with occasional
symptoms requiring intermittent treatment.
• When prescribing PPIs, providers must be aware of short vs. long-term course of
treatment and plan accordingly while taking the patients overall health into
consideration.
• In reviewing the literature, surgical treatment may be more efficacious than
treatment with PPIs.
• After surgery, the amount of PPI dose required was generally found to be less than
prior to surgery, which may help avoid some of the complications of long-term
PPI use.
• Lal et al. (2017) lists surgery as the better option for long-term control of
symptoms and for preventing new onset as well as regression of Barrett’s
metaplasia.
• In reviewing the research, there appears to be a strong correlation to long-term
PPI use and kidney failure, dementia, and myocardial infarction.
• There is some argument to the belief that PPIs cause osteoporosis, although this is
still being debated.

Applicability to Clinical
Practice

• PPIs are one of the most commonly prescribed medications by primary care
providers (PCPs).
• PPIs are available by prescription and over-the-counter.
• Specific populations may be at greater risk of harm from PPI use.
• Many factors should be weighted when determining treatment like severity of
symptoms, patient life expectancy, quality of life, other chronic conditions,
surgical candidacy, and adherence to treatment regimens.
• American Gastroenterological Association gives lifestyle changes a grade B
recommendation. These include elevating the head of the bed and avoiding trigger
foods. (Kahrilas et. al., 2008)
• Monitor those on PPIs for deterioration using recommended screening such as
basic lab draws and DEXA scanning.
• PCPs should discuss complications and treatment options with patients to allow
them to make an informed decision on their clinical course for common GI
conditions like GERD, H. pylori, and duodenal and peptic ulcers.
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